Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID
ADX-102-DED-013
Phase 2 small_molecule completed
Quick answer
Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID for Dry Eye is a Phase 2 program (small_molecule) at Aldeyra Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aldeyra Therapeutics
- Indication
- Dry Eye
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed